Official ESCRS | European Society of Cataract & Refractive Surgeons
Lisbon 2017 Delegate Registration Programme Exhibition Virtual Exhibition Satellites OneWorld Travel Discount
escrs app advert

Posters

Search Title by author or title

Surgical management of uveitis-glaucoma-hyphema syndrome

Poster Details

First Author: R.Vaiciuliene LITHUANIA

Co Author(s):    V. Jasinskas                    

Abstract Details

Purpose:

To report tactics of surgical management of uveitis-glaucoma-hyphema (UGH) syndrome utilization tailoring modified Siepser slip-knot technique for intraocular lens (IOL) suturing to the iris.

Setting:

Department of Ophthalmology, Lithuanian University of Health Sciences, Kaunas, Lithuania

Methods:

A 72-years-old patient underwent an uneventful cataract surgery with implantation of posterior chamber multifocal IOL (AcrySof IQ ReSTOR) in both eyes 8 years prior. He had several episodes with blurring vision and pain of his left eye in 2016. On examination, best-corrected visual acuity (BCVA) was 0.2, intraocular pressure �â�€�“ 40 mmHg, slit-lamp examination revealed cells in the anterior chamber, microhyphema, pseudophakodonesis and transillumination in iris periphery. IOL was stabilized by suturing of haptic with the anterior capsule to the iris periphery at 6 o�â�€�™clock using modified Siepser slip-knot technique positioning the knot behind the iris in December 2016.

Results:

The patient has been on regular follow-up with no further episodes of UGH syndrome. Three months after surgery BCVA was 1.0, intraocular pressure - 12 mmHg without antiglaucoma medications. Slit-lamp examination disclosed circular pupil, stable, but slightly decentered IOL, a still identifiable defect of the iris, but no anterior chamber inflammation or pigment dispersion. No cystoid macular edema developed.

Conclusions:

Suturing of IOL haptic/s to the iris under direct visual control precisely in the anticipated location leads to safe IOL stabilization. Proper immobilization of the haptic�â�€�™s cut off bleeding, restored VA and normalized IOP in our case.

Financial Disclosure:

NONE

Back to Poster listing